This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
Robert Screaton
Sunnybrook Research Institute
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4917-9473
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Breast cancer (BC) is a leading cause of death in women[1]. Women with Locally Advanced Breast Cancer (LABC) have high risk disease with either large primary breast tumours and/or lymph node involvement. While neoadjuvant chemotherapy eradicates breast cancer in approximately one-third of cases prior to surgery, almost 70% of patients have residual disease and many will require additional chemotherapy post-operatively. Improving pre-operative efficacy of neoadjuvant systemic treatments while reducing their iatrogenicities are critical unmet needs.
Methods: Here, we develop an RNA interference (RNAi) screening approach using conditionally reprogrammed primary LABC biopsies to identify genes of the mitochondrial Solute Ligand Carrier 25 (SLC25) family that support LABC cell viability.
Results: We report that silencing SLC25A12, -A15, and -A18 genes, involved in glutamate and ornithine flux, augment 5-fluorouracil (5FU) cytotoxic effectiveness in LABC cells.
Conclusions: Our data suggest glutamate metabolism may be a tumour-specific metabolic vulnerability in LABC. Furthermore, we demonstrate that RNAi screening in conditionally reprogrammed primary human breast cells can identify novel targets for the development of non-genotoxic BC treatments.
Keywords
SLC25, mitochondria, breast cancer, high-throughput screening (HTS), locally advanced breast cancer, RNA interference (RNAi), primary human cells
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 03 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
Learn more about our company.
This is a preprint. It has not completed peer review.
Research article
Robert Screaton
Sunnybrook Research Institute
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4917-9473
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 03 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Breast cancer (BC) is a leading cause of death in women[1]. Women with Locally Advanced Breast Cancer (LABC) have high risk disease with either large primary breast tumours and/or lymph node involvement. While neoadjuvant chemotherapy eradicates breast cancer in approximately one-third of cases prior to surgery, almost 70% of patients have residual disease and many will require additional chemotherapy post-operatively. Improving pre-operative efficacy of neoadjuvant systemic treatments while reducing their iatrogenicities are critical unmet needs.
Methods: Here, we develop an RNA interference (RNAi) screening approach using conditionally reprogrammed primary LABC biopsies to identify genes of the mitochondrial Solute Ligand Carrier 25 (SLC25) family that support LABC cell viability.
Results: We report that silencing SLC25A12, -A15, and -A18 genes, involved in glutamate and ornithine flux, augment 5-fluorouracil (5FU) cytotoxic effectiveness in LABC cells.
Conclusions: Our data suggest glutamate metabolism may be a tumour-specific metabolic vulnerability in LABC. Furthermore, we demonstrate that RNAi screening in conditionally reprogrammed primary human breast cells can identify novel targets for the development of non-genotoxic BC treatments.
Figure 1
Figure 2
Figure 3
Loading...